Cite
HARVARD Citation
Liu, H. et al. (2023). Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate‐risk acute myeloid leukemia in first complete remission undergoing auto‐HSCT: An open‐label, multicenter, randomized phase 3 trial. American journal of hematology. 98 (3), pp. 408-412. [Online].